CEO Carrie Eglinton Manner was paid $4,292,228 in fiscal year 2025, ↓ down 23.4% from fiscal year 2024, the 47th percentile of its disclosed peer group (SEC filing 0001116463-26-000032 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$4,292,228 ↓ Carrie Eglinton Manner total, FY2025 | 47th CEO pay percentile vs peers | 54:1 CEO-to-median pay ratio | 87.87% Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
Ask our research desk — $99, 24h, every figure cited to its filing.
OSUR's next annual pay disclosure, estimated May 26, 2027.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Carrie Eglinton Manner | $721,000 | $0 | $3,394,188 | $0 | $173,040 | $0 | $4,000 | $4,292,228 |
| President and Chief Executive Officer | ||||||||
| Kathleen Weber | 421,145 | 0 | 647,020 | 0 | 0 | 0 | 768,270 | 1,836,435 |
| Former Chief Product Officer | ||||||||
| Kenneth McGrath | 512,000 | 0 | 738,768 | 0 | 61,440 | 0 | 4,000 | 1,316,208 |
| Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Carrie Eglinton Manner | $4,292,228 | $5,602,298 | $6,701,767 | ↓ −1,310,070 |
| Kathleen Weber | 1,836,435 | 1,397,738 | 1,680,331 | ↑ +438,697 |
| Kenneth McGrath | 1,316,208 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read Orasure Technologies's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper OSUR reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
How we handle your data → Privacy
Each company listed discloses OSUR in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named OSUR in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
One page per officer: the same table above, read for one person at a time — his own figure and every fiscal year the register holds.
| Executive | Role | FY2025 total |
|---|---|---|
| Carrie Eglinton Manner | CEO | $4,292,228 |
| Kathleen Weber | Chief Product Officer | $1,836,435 |
| Kenneth McGrath | CFO | $1,316,208 |
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2025 total |
|---|---|---|
| David J. Shulkin | Independent Director | $246,076 |
| John D. Bertrand | Independent Director | — |
| John P. Kenny | Chair of the Board | $267,429 |
| Lelio Marmora | Independent Director | $249,996 |
| Mara G. Aspinall | Former director (through FY2025) | $277,938 |
| Nancy J. Gagliano | Independent Director | $267,627 |
| Robert W. McMahon | Independent Director | $259,996 |
| Steven K. Boyd | Independent Director | $111,368 |
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| John D. Bertrand | Director | 2026-05-12 | A | 33,661 | $0 | $0 | Common | Form 4 ↗ |
| Steven K. Boyd | Director | 2026-05-12 | A | 25,000 | 3 | 74,500 | Common | Form 4 ↗ |
| Robert W. McMahon | Director | 2026-05-13 | D | 22,888 | 3 | 69,122 | Common | Form 4 ↗ |
| Nancy J. Gagliano | Director | 2026-05-13 | D | 21,305 | 3 | 64,341 | Common | Form 4 ↗ |
| Lelio Marmora | Director | 2026-05-13 | D | 28,406 | 3 | 85,786 | Common | Form 4 ↗ |
| Steven K. Boyd | Director | 2026-05-13 | A | 25,000 | 3 | 75,500 | Common | Form 4 ↗ |
| Steven K. Boyd | Director | 2026-05-14 | A | 25,000 | 3 | 74,750 | Common | Form 4 ↗ |
| John D. Bertrand | Director | 2026-06-03 | A | 46,106 | 0 | 0 | Common | Form 4 ↗ |
| Lelio Marmora | Director | 2026-06-03 | A | 46,106 | 0 | 0 | Common | Form 4 ↗ |
| Robert W. McMahon | Director | 2026-06-03 | A | 46,106 | 0 | 0 | Common | Form 4 ↗ |
| Steven K. Boyd | Director | 2026-06-03 | A | 46,106 | 0 | 0 | Common | Form 4 ↗ |
| John P. Kenny | Director | 2026-06-03 | A | 46,106 | 0 | 0 | Common | Form 4 ↗ |
| Nancy J. Gagliano | Director | 2026-06-03 | A | 46,106 | 0 | 0 | Common | Form 4 ↗ |
| Steven K. Boyd | Director | 2026-06-26 | A | 3,666 | 4 | 16,250 | Common | Form 4 ↗ |
| John P. Kenny | Director | 2026-09-06 | D | 5,116 | 3 | 17,535 | Common | Form 4 ↗ |
| Steven K. Boyd | Director | 2026-09-29 | A | 4,797 | 4 | 18,612 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Kenneth McGrath | RSU | 2025-03-01 | — | — | 100,647 | — | $348,249 |
| Carrie Eglinton Manner | PSU | 2025-03-01 | 231,207 | 462,414 | — | 693,621 | 1,988,380 |
| Kathleen Weber | RSU | 2025-03-01 | — | — | 88,148 | — | 305,001 |
| Carrie Eglinton Manner | RSU | 2025-03-01 | — | — | 462,414 | — | 1,599,999 |
| Kenneth McGrath | PSU | 2025-03-01 | 50,324 | 100,648 | — | 150,972 | 432,786 |
| Kathleen Weber | PSU | 2025-03-01 | 44,074 | 88,148 | — | 132,221 | 379,036 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Kenneth McGrath | $348,249 | $432,786 | $0 | 55.4% |
| Carrie Eglinton Manner | 1,599,999 | 1,988,380 | 0 | 55.4% |
| Kathleen Weber | 305,001 | 379,036 | 0 | 55.4% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Kenneth McGrath | RSU | 100,647 | — | $243,566 |
| Kenneth McGrath | RSU | 17,876 | — | 43,260 |
| Carrie Eglinton Manner | RSU | 173,792 | — | 420,577 |
| Carrie Eglinton Manner | RSU | 462,414 | — | 1,119,042 |
| Carrie Eglinton Manner | PSU | 129,033 | — | 312,259 |
| Kenneth McGrath | PSU | 26,815 | — | 64,891 |
| Carrie Eglinton Manner | PSU | 462,414 | — | 1,119,042 |
| Carrie Eglinton Manner | PSU | 260,688 | — | 315,432 |
| Kenneth McGrath | PSU | 100,648 | — | 243,568 |
| Carrie Eglinton Manner | RSU | 86,022 | — | 208,173 |
| Kenneth McGrath | RSU | 39,173 | — | 94,799 |
| Kenneth McGrath | PSU | 58,759 | — | 71,098 |
The Company's compensation program is performance-based and is designed to pay executives for performance by offering rewards for the achievement of pre-determined objectives. It is designed to align the interests of executives with those of stockholders, provide long-term incentives, and set compensation at levels sufficiently competitive to attract, retain, and motivate high-quality executives.
| CEO STI target (% of salary) | 100% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Pay Governance |
| Clawback policy | true |
| Anti-hedging | True |
| Anti-pledging | True |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-03 | 45,225,131 | 6,179,090 | 62,939 | 87.87% | Passed |
| 2025 | 2025-05-14 | 51,997,355 | 6,477,192 | 203,773 | 88.61% | Passed |
| 2024 | 2024-05-14 | 57,538,779 | 4,472,675 | 111,471 | 92.62% | Passed |
| 2023 | 2023-05-16 | 39,391,642 | 20,030,810 | 69,297 | 66.21% | Passed |
| 2022 | 2022-05-17 | 56,687,157 | 1,535,739 | 113,706 | 97.36% | Passed |
| 2021 | 2021-05-18 | 50,490,819 | 2,320,406 | 386,653 | 95.61% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-06-03 | 87.87%a |
| 2025 | 2025-05-14 | 88.61%b |
| 2024 | 2024-05-14 | 92.62%c |
a. Approved under the standard stated in the filing — “Abstentions will have the effect of a vote "against" the outcome of this proposal, and broker non-votes, if any, will have no effect on the outcome of this proposal.”.
b. Approved under the standard stated in the filing — “Abstentions will have the effect of voting against this proposal.”.
c. Approved under the standard stated in the filing — “Abstentions will have the effect of voting against this proposal.”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 54 : 1 |
|---|---|
| CEO total compensation | $4,292,228 |
| Median employee compensation | $79,397 |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Mara G. AspinallIndependent · Audit · Departed during FY | $92,942 | $184,996 | $0 | $0 | $0 | $277,938 |
| Nancy J. GaglianoIndependent · Compensation (Chair) · Nominating and Corporate Governance (Chair) | 82,631 | 184,996 | 0 | 0 | 0 | 267,627 |
| John P. KennyIndependent · Board Chair · Compensation | 82,433 | 184,996 | 0 | 0 | 0 | 267,429 |
| Robert W. McMahonIndependent · Audit (Chair) | 75,000 | 184,996 | 0 | 0 | 0 | 259,996 |
| Lelio MarmoraIndependent · Audit · Nominating and Corporate Governance | 65,000 | 184,996 | 0 | 0 | 0 | 249,996 |
| David J. ShulkinIndependent · Compensation | 61,080 | 184,996 | 0 | 0 | 0 | 246,076 |
| Steven K. BoydIndependent · Audit · Nominating and Corporate Governance | 11,368 | 100,000 | 0 | 0 | 0 | 111,368 |
| John D. BertrandIndependent · Nominating and Corporate Governance · Newly elected | 0 | 0 | 0 | 0 | 0 | 0 |
| Carrie Eglinton MannerEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $55,000 |
|---|---|
| Annual equity retainer | $185,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 20,000 / 20,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $470,454 |
| Equity awards (grant-date value) | $1,209,976 |
| All other compensation | $0 |
| Total cost of the board | $1,680,430 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Orasure Technologies names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Orasure Technologies.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Castle Biosciences, Inc. | 2025 | D. Christian Koch | $1,493,000 | $6,376,929 | $2,612,603 | $0 | $11,359,438 |
| 2 | Maravai LifeSciences, Inc. | 2025 | Bernd Brust | 388,863 | 7,660,000 | 1,460,000 | 425,343 | 10,129,708 |
| 3 | Standard BioTools Inc. | 2025 | Michael Egholm | 680,256 | 5,337,883 | 1,671,363 | 1,120,000 | 8,823,502 |
| 4 | Mesa Laboratories, Inc. | 2026 | Gary Owens | 808,846 | 4,700,017 | 0 | 1,120,000 | 6,643,208 |
| 5 | Fulgent Genetics, Inc. | 2025 | Ming Hsieh | 1,000,000 | 4,000,000 | 0 | 1,207,000 | 6,207,000 |
| 6 | AngioDynamics, Inc. | 2026 | James Clemmer | 828,171 | 3,689,866 | 0 | 1,502,491 | 6,060,145 |
| 7 | Quanterix Corporation | 2025 | Masoud Toloue | 670,950 | 1,170,000 | 2,729,998 | 674,172 | 5,250,745 |
| 8 | Pacific Biosciences of California, Inc. | 2025 | Christian Henry | 748,250 | 1,151,013 | 1,696,278 | 714,305 | 4,309,846 |
| 9 | Orasure Technologies | 2025 | Carrie Eglinton Manner | 721,000 | 3,394,188 | 0 | 173,040 | 4,292,228 |
| 10 | Cerus Corporation | 2025 | William Greenman | 793,750 | 2,242,585 | 0 | 756,000 | 3,794,657 |
| 11 | Personalis, Inc. | 2025 | Christopher Hall | 618,000 | 853,050 | 1,784,728 | 247,200 | 3,505,978 |
| 12 | Tactile Systems Technology, Inc. | 2025 | Sheri Dodd | 675,000 | 2,019,978 | 0 | 737,438 | 3,466,916 |
| 13 | BioLife Solutions, Inc. | 2025 | Kristen Fortney | 600,000 | 0 | 1,941,390 | 330,000 | 2,886,590 |
| 14 | Cryoport, Inc. | 2025 | Jerrell Shelton | 967,845 | 192,300 | 306,869 | 908,510 | 2,375,524 |
| 15 | Codexis, Inc. | 2025 | Alison Moore | 524,732 | 255,994 | 1,065,223 | 463,125 | 2,323,279 |
| 16 | Biodesix, Inc. | 2025 | Scott Hutton | 643,404 | 356,849 | 524,437 | 710,280 | 2,238,470 |
| 17 | Lifecore Biomedical, Inc. | 2025 | Paul Josephs | 550,000 | 274,996 | — | — | 1,115,305 |
| — | Alpha Teknova, Inc. | — | — | — | — | — | — | not in coverage universe |
| — | Harvard Bioscience, Inc. | — | — | — | — | — | — | not in coverage universe |
| — | Cytek Biosciences, Inc. | — | — | — | — | — | — | not in coverage universe |
| — | Exagen Inc. | — | — | — | — | — | — | not in coverage universe |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Orasure Technologies | 24.0% | RSU 50 · PSU 50 | Yes — Relative TSR performance vs peer group | Pay Governance |
| Alpha Teknova, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| AngioDynamics, Inc. | 180% | PSU 50 · RSU 50 | No | Meridian Compensation Partners, LLC |
| Biodesix, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| BioLife Solutions, Inc. | not disclosed | Option 100 | not disclosed | Alpine Rewards LLC |
| Castle Biosciences, Inc. | not disclosed | PSU 33 · RSU 33 · Options 33 | No | Willis Towers Watson |
| Cerus Corporation | 126% | not disclosed | No | Alpine |
| Codexis, Inc. | 95% | not disclosed | not disclosed | Pearl Meyer |
| Cryoport, Inc. | 92.2% | not disclosed | not disclosed | Frederic W. Cook & Co., Inc. |
| Cytek Biosciences, Inc. | not disclosed | Option 50 · RSU 50 | not disclosed | Meridian Compensation Partners, LLC |
| Exagen Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Fulgent Genetics, Inc. | 120.7% | PSU 60 · RSU 40 | No | USI |
| Harvard Bioscience, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Lifecore Biomedical, Inc. | not disclosed | not disclosed | not disclosed | Frederic W. Cook & Co. |
| Maravai LifeSciences, Inc. | not disclosed | not disclosed | No | Meridian Compensation Partners, LLC |
| Mesa Laboratories, Inc. | 125% | PSU 50 · RSU 50 | No | Frederic W. Cook & Co, Inc. |
| Pacific Biosciences of California, Inc. | 95% | not disclosed | not disclosed | Aon Human Capital Solutions |
| Personalis, Inc. | not disclosed | not disclosed | not disclosed | Aon |
| Quanterix Corporation | 95% | Options 70 · RSU 30 | not disclosed | PayGov |
| Standard BioTools Inc. | 160% | not disclosed | not disclosed | Pearl Meyer |
| Tactile Systems Technology, Inc. | 115% | PSU 50 · RSU 50 | No | Aon Consulting, Inc. |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Carrie Eglinton Manner | DEF 14A | 2026-04-30 | 0001116463-26-000032 | Section “SUMMARY COMPENSATION TABLE” · page 55. As printed: 4,292,228. Filing ↗machine: t152 · r2 · c21 · span 850376–850385 |
| 2 | Section 01, Kathleen Weber | DEF 14A | 2026-04-30 | 0001116463-26-000032 | Section “SUMMARY COMPENSATION TABLE” · page 55. As printed: 1,836,435. Filing ↗machine: span 874687–874696 |
| 3 | Section 01, Kenneth McGrath | DEF 14A | 2026-04-30 | 0001116463-26-000032 | Section “SUMMARY COMPENSATION TABLE” · page 55. As printed: 1,316,208. Filing ↗machine: span 862741–862750 |
| 4 | Section 03, Kenneth McGrath RSU | DEF 14A | 2026-04-30 | 0001116463-26-000032 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t143 · r5 · c3 · span 795857–795864 |
| 5 | Section 03, Carrie Eglinton Manner PSU | DEF 14A | 2026-04-30 | 0001116463-26-000032 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t143 · r2 · c3 · span 794196–794203 |
| 6 | Section 03, Kathleen Weber RSU | DEF 14A | 2026-04-30 | 0001116463-26-000032 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t143 · r9 · c3 · span 797817–797823 |
| 7 | Section 03, Carrie Eglinton Manner RSU | DEF 14A | 2026-04-30 | 0001116463-26-000032 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t143 · r2 · c3 · span 794196–794203 |
| 8 | Section 03, Kenneth McGrath PSU | DEF 14A | 2026-04-30 | 0001116463-26-000032 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t143 · r5 · c4 · span 796169–796176 |
| 9 | Section 03, Kathleen Weber PSU | DEF 14A | 2026-04-30 | 0001116463-26-000032 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t143 · r9 · c3 · span 797817–797823 |
| 10 | Section 07, pay ratio | DEF 14A | 2026-04-30 | 0001116463-26-000032 | Section “CEO Pay Ratio”. As printed: 54 : 1. Filing ↗ |
| 11 | Section 08, Mara G. Aspinall | DEF 14A | 2026-04-30 | 0001116463-26-000032 | Section “Director Compensation”. As printed: 277,938. Filing ↗machine: t180 · r2 · c18 · span 1266164–1266291 |
| 12 | Section 08, Nancy J. Gagliano | DEF 14A | 2026-04-30 | 0001116463-26-000032 | Section “Director Compensation”. As printed: 267,627. Filing ↗machine: t180 · r6 · c18 · span 1283173–1283300 |
| 13 | Section 08, John P. Kenny | DEF 14A | 2026-04-30 | 0001116463-26-000032 | Section “Director Compensation”. As printed: 267,429. Filing ↗machine: t180 · r7 · c18 · span 1287556–1287683 |
| 14 | Section 08, Robert W. McMahon | DEF 14A | 2026-04-30 | 0001116463-26-000032 | Section “Director Compensation”. As printed: 259,996. Filing ↗machine: t180 · r8 · c18 · span 1292314–1292441 |
| 15 | Section 08, Lelio Marmora | DEF 14A | 2026-04-30 | 0001116463-26-000032 | Section “Director Compensation”. As printed: 249,996. Filing ↗machine: t180 · r5 · c18 · span 1278963–1279090 |
| 16 | Section 08, David J. Shulkin | DEF 14A | 2026-04-30 | 0001116463-26-000032 | Section “Director Compensation”. As printed: 246,076. Filing ↗machine: t180 · r4 · c18 · span 1274760–1274887 |
| 17 | Section 08, Steven K. Boyd | DEF 14A | 2026-04-30 | 0001116463-26-000032 | Section “Director Compensation”. As printed: 111,368. Filing ↗machine: t180 · r3 · c18 · span 1270548–1270675 |
| 18 | Section 08, John D. Bertrand | DEF 14A | 2026-04-30 | 0001116463-26-000032 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 19 | Section 08, Carrie Eglinton Manner | DEF 14A | 2026-04-30 | 0001116463-26-000032 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 20 | Section 02, John D. Bertrand 2026-05-12 | Form 4 | 2026-05-14 | 0001470831-26-000442 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 21 | Section 02, Steven K. Boyd 2026-05-12 | Form 4 | 2026-05-14 | 0001470831-26-000443 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 22 | Section 02, Robert W. McMahon 2026-05-13 | Form 4 | 2026-05-14 | 0001470831-26-000437 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 23 | Section 02, Nancy J. Gagliano 2026-05-13 | Form 4 | 2026-05-14 | 0001470831-26-000436 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 24 | Section 02, Lelio Marmora 2026-05-13 | Form 4 | 2026-05-14 | 0001470831-26-000438 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 25 | Section 02, Steven K. Boyd 2026-05-13 | Form 4 | 2026-05-14 | 0001470831-26-000443 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 26 | Section 02, Steven K. Boyd 2026-05-14 | Form 4 | 2026-05-14 | 0001470831-26-000443 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 27 | Section 02, John D. Bertrand 2026-06-03 | Form 4 | 2026-06-05 | 0001470831-26-000516 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 28 | Section 02, Lelio Marmora 2026-06-03 | Form 4 | 2026-06-05 | 0001470831-26-000518 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 29 | Section 02, Robert W. McMahon 2026-06-03 | Form 4 | 2026-06-05 | 0001470831-26-000520 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 30 | Section 02, Steven K. Boyd 2026-06-03 | Form 4 | 2026-06-05 | 0001470831-26-000515 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 31 | Section 02, John P. Kenny 2026-06-03 | Form 4 | 2026-06-05 | 0001470831-26-000517 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 32 | Section 02, Nancy J. Gagliano 2026-06-03 | Form 4 | 2026-06-05 | 0001470831-26-000519 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 33 | Section 02, Steven K. Boyd 2026-06-26 | Form 4 | 2026-06-30 | 0001470831-26-000683 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 34 | Section 02, John P. Kenny 2026-09-06 | Form 4 | 2026-09-09 | 0001470831-26-000880 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 35 | Section 02, Steven K. Boyd 2026-09-29 | Form 4 | 2026-10-01 | 0001470831-26-000918 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 36 | Section 06, 2026 vote | Form 8-K | 2026-06-03 | 0001116463-26-000043 | Item 5.07 · say-on-pay result. As reported: 87.87% (votes for as printed: 45,225,131). Filing ↗ |
| 37 | Section 06, 2025 vote | Form 8-K | 2025-05-14 | 0001628280-25-025491 | Item 5.07 · say-on-pay result. As reported: 88.61% (votes for as printed: 51,997,355). Filing ↗ |
| 38 | Section 06, 2024 vote | Form 8-K | 2024-05-17 | 0001628280-24-024025 | Item 5.07 · say-on-pay result. As reported: 92.62% (votes for as printed: 57,538,779). Filing ↗ |
| 39 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 40 | Section 03b vehicle mix (computed) | Computed | — | — | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 41 | Section 09b board cost (computed) | Computed | — | — | Cash 470,454 + equity 1,209,976 + all other 0 = 1,680,430, summed across the director compensation table rows.machine: formula: Σ = 1,680,430 |
| 42 | Castle Biosciences, Inc., Section 10b CEO total | DEF 14A | 2026-03-17 | 0001193125-26-109193 | CEO total compensation as printed in Castle Biosciences, Inc.'s own proxy. As printed: 11,359,438. Filing ↗machine: t108 · r2 · c44 · span 570250–570260 |
| 43 | Maravai LifeSciences, Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001823239-26-000014 | CEO total compensation as printed in Maravai LifeSciences, Inc.'s own proxy. As printed: 10,129,708. Filing ↗machine: t21 · r3 · c20 · span 502645–502655 |
| 44 | Standard BioTools Inc., Section 10b CEO total | DEF 14A | 2026-04-27 | 0001140361-26-017100 | CEO total compensation as printed in Standard BioTools Inc.'s own proxy. As printed: 8,823,502. Filing ↗machine: r2 · c22 · span 553256–553266 |
| 45 | Mesa Laboratories, Inc., Section 10b CEO total | DEF 14A | 2026-07-22 | 0000724004-26-000071 | CEO total compensation as printed in Mesa Laboratories, Inc.'s own proxy. As printed: 6,643,208. Filing ↗machine: r3 · c24 · span 580946–580955 |
| 46 | Fulgent Genetics, Inc., Section 10b CEO total | DEF 14A | 2026-03-31 | 0001674930-26-000020 | CEO total compensation as printed in Fulgent Genetics, Inc.'s own proxy. As printed: 6,207,000. Filing ↗machine: r3 · c22 · span 533279–533288 |
| 47 | AngioDynamics, Inc., Section 10b CEO total | DEF 14A | 2026-10-08 | 0001140361-26-039022 | CEO total compensation as printed in AngioDynamics, Inc.'s own proxy. As printed: 6,060,145. Filing ↗machine: r2 · c27 · span 739870–739879 |
| 48 | Quanterix Corporation, Section 10b CEO total | DEF 14A | 2026-04-24 | 0001104659-26-048166 | CEO total compensation as printed in Quanterix Corporation's own proxy. As printed: 5,250,745. Filing ↗machine: t18 · r1 · c47 · span 503076–503085 |
| 49 | Pacific Biosciences of California, Inc., Section 10b CEO total | DEF 14A | 2026-04-23 | 0001299130-26-000064 | CEO total compensation as printed in Pacific Biosciences of California, Inc.'s own proxy. As printed: 4,309,846. Filing ↗machine: r2 · c48 · span 876974–876983 |
| 50 | Orasure Technologies (subject), Section 10b CEO total | DEF 14A | 2026-04-30 | 0001116463-26-000032 | CEO total compensation as printed in Orasure Technologies's own proxy. As printed: 4,292,228. Filing ↗machine: t152 · r2 · c21 · span 850376–850385 |
| 51 | Cerus Corporation, Section 10b CEO total | DEF 14A | 2026-04-22 | 0001020214-26-000011 | CEO total compensation as printed in Cerus Corporation's own proxy. As printed: 3,794,657. Filing ↗machine: span 1301658–1301667 |
| 52 | Personalis, Inc., Section 10b CEO total | DEF 14A | 2026-04-02 | 0001193125-26-140038 | CEO total compensation as printed in Personalis, Inc.'s own proxy. As printed: 3,505,978. Filing ↗machine: r2 · c25 · span 489936–489945 |
| 53 | Tactile Systems Technology, Inc., Section 10b CEO total | DEF 14A | 2026-03-25 | 0001104659-26-034206 | CEO total compensation as printed in Tactile Systems Technology, Inc.'s own proxy. As printed: 3,466,916. Filing ↗machine: r3 · c12 · span 865797–865806 |
| 54 | BioLife Solutions, Inc., Section 10b CEO total | DEF 14A | 2026-04-21 | 0001193125-26-166738 | CEO total compensation as printed in BioLife Solutions, Inc.'s own proxy. As printed: 2,886,590. Filing ↗machine: r2 · c19 · span 428555–428564 |
| 55 | Cryoport, Inc., Section 10b CEO total | DEF 14A | 2026-04-22 | 0001140361-26-016129 | CEO total compensation as printed in Cryoport, Inc.'s own proxy. As printed: 2,375,524. Filing ↗machine: t277 · r2 · c22 · span 1285130–1285139 |
| 56 | Codexis, Inc., Section 10b CEO total | DEF 14A | 2026-04-28 | 0001193125-26-186994 | CEO total compensation as printed in Codexis, Inc.'s own proxy. As printed: 2,323,279. Filing ↗machine: r2 · c27 · span 319928–319937 |
| 57 | Biodesix, Inc., Section 10b CEO total | DEF 14A | 2026-04-09 | 0001193125-26-149633 | CEO total compensation as printed in Biodesix, Inc.'s own proxy. As printed: 2,238,470. Filing ↗machine: r4 · c34 · span 377658–377667 |
| 58 | Lifecore Biomedical, Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001005286-26-000012 | CEO total compensation as printed in Lifecore Biomedical, Inc.'s own proxy. As printed: 1,115,305. Filing ↗ |
| 59 | Section 10a, Cerus Corporation reciprocity | DEF 14A | — | 0001020214-26-000011 | Cerus Corporation names Orasure Technologies in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 60 | Section 10a, Codexis, Inc. reciprocity | DEF 14A | — | 0001193125-25-093503 | Codexis, Inc.'s most recent proxy was read; its disclosed peer group does not include Orasure Technologies. Filing ↗ |
| 61 | Section 10a, Personalis, Inc. reciprocity | DEF 14A | — | 0001193125-26-140038 | Personalis, Inc. names Orasure Technologies in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 62 | Section 10a, Fulgent Genetics, Inc. reciprocity | DEF 14A | — | 0001674930-26-000020 | Fulgent Genetics, Inc.'s most recent proxy was read; its disclosed peer group does not include Orasure Technologies. Filing ↗ |
| 63 | Section 10a, Lifecore Biomedical, Inc. reciprocity | DEF 14A | — | 0001005286-26-000012 | Lifecore Biomedical, Inc. names Orasure Technologies in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 64 | Section 10a, Quanterix Corporation reciprocity | DEF 14A | — | 0001104659-26-048166 | Quanterix Corporation's most recent proxy was read; its disclosed peer group does not include Orasure Technologies. Filing ↗ |
| 65 | Section 10a, Standard BioTools Inc. reciprocity | DEF 14A | — | 0001140361-26-017100 | Standard BioTools Inc. names Orasure Technologies in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 66 | Section 10a, Tactile Systems Technology, Inc. reciprocity | DEF 14A | — | 0001104659-26-034206 | Tactile Systems Technology, Inc.'s most recent proxy was read; its disclosed peer group does not include Orasure Technologies. Filing ↗ |
| 67 | Section 10a, Maravai LifeSciences, Inc. reciprocity | DEF 14A | — | 0001823239-26-000014 | Maravai LifeSciences, Inc.'s most recent proxy was read; its disclosed peer group does not include Orasure Technologies. Filing ↗ |
| 68 | Section 10a, Pacific Biosciences of California, Inc. reciprocity | DEF 14A | — | 0001299130-26-000064 | Pacific Biosciences of California, Inc.'s most recent proxy was read; its disclosed peer group does not include Orasure Technologies. Filing ↗ |
| 69 | Section 10a, AngioDynamics, Inc. reciprocity | DEF 14A | — | 0001140361-26-039022 | AngioDynamics, Inc.'s most recent proxy was read; its disclosed peer group does not include Orasure Technologies. Filing ↗ |
| 70 | Section 10a, Mesa Laboratories, Inc. reciprocity | DEF 14A | — | 0000724004-26-000071 | Mesa Laboratories, Inc.'s most recent proxy was read; its disclosed peer group does not include Orasure Technologies. Filing ↗ |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.